DE69330206T2
(de)
*
|
1992-04-02 |
2002-02-14 |
Smithkline Beecham Corp |
Verbindungen zur behandlung von allergischen und entzündlichen erkrankungen
|
SI0710109T1
(en)
*
|
1993-06-18 |
2005-02-28 |
Smithkline Beecham Corporation |
Method for identifying a PDE IV inhibitor
|
US5780667A
(en)
*
|
1993-10-01 |
1998-07-14 |
Smithkline Beecham Corporation |
Compounds, compositions and treatment of allergies and inflammation therewith
|
US6013827A
(en)
*
|
1994-03-11 |
2000-01-11 |
Smithkline Beecham Corporation |
Compounds
|
GB9404706D0
(en)
*
|
1994-03-11 |
1994-04-27 |
Smithkline Beecham Corp |
Compounds
|
US5998428A
(en)
*
|
1995-05-31 |
1999-12-07 |
Smithkline Beecham Corporation |
Compounds and methods for treating PDE IV-related diseases
|
WO1996020174A1
(en)
*
|
1994-12-23 |
1996-07-04 |
Smithkline Beecham Corporation |
1,3,3-(trisubstituted)cyclohexane monomers and related compounds
|
WO1996020162A1
(en)
*
|
1994-12-23 |
1996-07-04 |
Smithkline Beecham Corporation |
1,4,4-(trisubstituted)cyclohex-1-ene dimers and related compounds
|
WO1996020161A1
(en)
*
|
1994-12-23 |
1996-07-04 |
Smithkline Beecham Corporation |
4,4-(disubstituted)cyclohexan-1-ol dimers and related compounds
|
ZA9510826B
(en)
*
|
1994-12-23 |
1996-06-20 |
Smithkline Beecham Corp |
3,3-(disubstituted)cyclohexan-1-ol monomers and related compounds
|
JPH10511658A
(ja)
*
|
1994-12-23 |
1998-11-10 |
スミスクライン・ビーチャム・コーポレイション |
4,4−(二置換)シクロヘキサン−1−オール単量体および関連する化合物
|
JPH10511391A
(ja)
*
|
1994-12-23 |
1998-11-04 |
スミスクライン・ビーチャム・コーポレイション |
3,3−(二置換)シクロヘキサン−1−オール二量体および関連化合物
|
AU705723B2
(en)
*
|
1995-05-18 |
1999-05-27 |
Altana Pharma Ag |
Cyclohexyl dihydrobenzofuranes
|
US5902824A
(en)
*
|
1995-05-18 |
1999-05-11 |
Byk Gulden Lomberg Chemische Fabrik Gmbh |
Phenyldihydrobenzofuranes
|
AR004471A1
(es)
*
|
1995-05-31 |
1998-12-16 |
Smithkline Beecham Corp |
Compuestos de ciclohexan-1-ol-4,4-disustituidos, utiles en el tratamiento de enfermedades alergicas e inflamatorias y composiciones farmaceuticas que lascontienen
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
US5891883A
(en)
*
|
1995-12-21 |
1999-04-06 |
Smithkline Beecham Corporation |
4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds
|
US6294573B1
(en)
|
1997-08-06 |
2001-09-25 |
Abbott Laboratories |
Reverse hydroxamate inhibitors of matrix metalloproteinases
|
US6235786B1
(en)
|
1997-08-06 |
2001-05-22 |
Abbott Laboratories |
Reverse hydroxamate inhibitors of matrix metalloproteinases
|
US6288261B1
(en)
|
1998-12-18 |
2001-09-11 |
Abbott Laboratories |
Inhibitors of matrix metalloproteinases
|
DZ3019A1
(fr)
*
|
1999-03-01 |
2005-05-20 |
Smithkline Beecham Corp |
Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.
|
US20020077276A1
(en)
*
|
1999-04-27 |
2002-06-20 |
Fredeking Terry M. |
Compositions and methods for treating hemorrhagic virus infections and other disorders
|
US20040220424A1
(en)
*
|
1999-08-06 |
2004-11-04 |
Smithkline Beecham Corporation |
Process for preparing acids via alpha-chloroepoxy esters
|
ECSP003599A
(es)
*
|
1999-08-06 |
2002-03-25 |
Smithkline Beecham Corp |
Procedimiento para preparar acidos a traves de alfa-coroepoxi-esteres
|
ATE320800T1
(de)
|
1999-08-21 |
2006-04-15 |
Altana Pharma Ag |
Synergistische kombination von roflumilast und salmeterol
|
US6572794B1
(en)
|
2000-07-24 |
2003-06-03 |
Essilor International Compagnie Generale D'optique |
Method of manufacturing a photochromic molded article
|
FR2816950B1
(fr)
|
2000-11-17 |
2003-02-14 |
Essilor Int |
Procede d'obtention d'un latex photochromique
|
FR2819258B1
(fr)
|
2001-01-11 |
2003-04-11 |
Essilor Int |
Procede d'obtention d'un latex photochromique stabilise, latex obtenu et application a l'optique ophtalmique
|
CA2385745C
(en)
|
2001-06-08 |
2015-02-17 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
CN102755646A
(zh)
|
2002-07-19 |
2012-10-31 |
艾博特生物技术有限公司 |
TNF α相关疾病的治疗
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
BRPI0409229A
(pt)
|
2003-04-01 |
2006-03-28 |
Applied Research Systems |
inibidores das fosfodiesterases na infertilidade
|
US20050085430A1
(en)
*
|
2003-07-31 |
2005-04-21 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
US20090274676A1
(en)
*
|
2003-07-31 |
2009-11-05 |
Robinson Cynthia B |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
US20050026883A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
US20050187278A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Pharmacia Corporation |
Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
|
JPWO2005037269A1
(ja)
*
|
2003-10-21 |
2006-12-28 |
住友製薬株式会社 |
新規ピペリジン誘導体
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
TWI439284B
(zh)
|
2004-04-09 |
2014-06-01 |
Abbvie Biotechnology Ltd |
用於治療TNFα相關失調症之多重可變劑量療法
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
KR101465456B1
(ko)
|
2005-05-16 |
2014-11-27 |
애브비 바이오테크놀로지 리미티드 |
미란성 다발관절염의 치료를 위한 tnf 억제제의 용도
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
US20070041905A1
(en)
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
CA2625664C
(en)
|
2005-10-21 |
2016-01-05 |
Novartis Ag |
Human antibodies against il13 and therapeutic uses
|
TWI424161B
(zh)
|
2005-11-01 |
2014-01-21 |
Abbvie Biotechnology Ltd |
利用生物標記診斷關節黏連脊椎炎之方法及組合物
|
GB0526244D0
(en)
|
2005-12-22 |
2006-02-01 |
Novartis Ag |
Organic compounds
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
EP3088410A3
(en)
|
2006-04-05 |
2016-12-28 |
AbbVie Biotechnology Ltd |
Antibody purification
|
EP2666478A3
(en)
|
2006-04-10 |
2014-10-22 |
AbbVie Biotechnology Ltd |
Uses and compositions for treatment of psoriasis
|
EP2666472A3
(en)
|
2006-04-10 |
2014-04-02 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of psoriatic arthritis
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
US8258141B2
(en)
|
2006-04-21 |
2012-09-04 |
Novartis Ag |
Organic compounds
|
EP2043711A4
(en)
|
2006-06-30 |
2017-08-30 |
AbbVie Biotechnology Ltd |
Automatic injection device
|
US20090286779A1
(en)
|
2006-09-29 |
2009-11-19 |
Novartis Ag |
Pyrazolopyrimidines as lipid kinase inhibitors
|
RU2009120389A
(ru)
|
2006-10-30 |
2010-12-10 |
Новартис АГ (CH) |
Гетероциклические соединения в качестве противовоспалительных агентов
|
DK2104535T3
(da)
|
2007-01-10 |
2011-04-04 |
Irm Llc |
Forbindelser og sammensætninger som kanalaktiverende proteaseinhibitorer
|
US20090182035A1
(en)
*
|
2007-04-11 |
2009-07-16 |
Alcon Research, Ltd. |
Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
|
RU2009141592A
(ru)
*
|
2007-04-11 |
2011-05-20 |
Алькон Рисерч, Лтд. (Us) |
ПРИМЕНЕНИЕ ИНГИБИТОРА TNFα В СОЧЕТАНИИ С АНТИГИСТАМИННЫМ СРЕДСТВОМ ДЛЯ ЛЕЧЕНИЯ АЛЛЕРГИЧЕСКОГО РИНИТА И АЛЛЕРГИЧЕСКОГО КОНЪЮНКТИВИТА
|
PL2155721T3
(pl)
|
2007-05-07 |
2011-07-29 |
Novartis Ag |
Związki organiczne
|
WO2008151257A2
(en)
|
2007-06-04 |
2008-12-11 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
EP2171451A4
(en)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
|
PE20091096A1
(es)
|
2007-12-10 |
2009-08-25 |
Novartis Ag |
Compuestos organicos
|
KR20100113557A
(ko)
|
2008-01-11 |
2010-10-21 |
노파르티스 아게 |
키나제 억제제로서의 피리미딘
|
WO2009149279A2
(en)
|
2008-06-04 |
2009-12-10 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
BRPI0915018A2
(pt)
|
2008-06-10 |
2015-10-27 |
Novartis Ag |
compostos orgânicos
|
WO2010009319A2
(en)
|
2008-07-16 |
2010-01-21 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
JP2012516345A
(ja)
|
2009-01-29 |
2012-07-19 |
ノバルティス アーゲー |
星細胞腫治療用置換ベンゾイミダゾール
|
WO2010127146A1
(en)
|
2009-04-29 |
2010-11-04 |
Abbott Biotechnology Ltd |
Automatic injection device
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
MX2012001838A
(es)
|
2009-08-12 |
2012-02-29 |
Novartis Ag |
Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
|
CN105078978A
(zh)
|
2009-08-17 |
2015-11-25 |
因特利凯公司 |
杂环化合物及其用途
|
EP2467383A1
(en)
|
2009-08-20 |
2012-06-27 |
Novartis AG |
Heterocyclic oxime compounds
|
BR112012007091A2
(pt)
*
|
2009-10-01 |
2016-04-19 |
Alcon Res Ltd |
composições de olopatadina e seus usos
|
CN102665715A
(zh)
|
2009-10-22 |
2012-09-12 |
沃泰克斯药物股份有限公司 |
治疗囊性纤维化和其他慢性疾病的组合物
|
US20110150891A1
(en)
|
2009-12-16 |
2011-06-23 |
Philip Bosch |
Methods of Treating Interstitial Cystitis
|
WO2011097301A2
(en)
|
2010-02-02 |
2011-08-11 |
Abbott Biotechnology Ltd. |
METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
JP5809242B2
(ja)
|
2010-04-21 |
2015-11-10 |
アッヴィ バイオテクノロジー リミテッド |
治療薬の制御送達のための装着型自動注入装置
|
WO2011146727A1
(en)
|
2010-05-19 |
2011-11-24 |
Philip Bosch |
Methods of treating interstitial cystitis
|
HUE039740T2
(hu)
|
2010-06-03 |
2019-01-28 |
Abbvie Biotechnology Ltd |
Alkalmazások és készítmények hidradenitis suppurativa (HS) kezelésére
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
US8637516B2
(en)
|
2010-09-09 |
2014-01-28 |
Irm Llc |
Compounds and compositions as TRK inhibitors
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
EP2667918B1
(en)
|
2011-01-24 |
2017-03-01 |
AbbVie Biotechnology Ltd |
Automatic injection devices having overmolded gripping surfaces
|
US20130324526A1
(en)
|
2011-02-10 |
2013-12-05 |
Novartis Ag |
[1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
EP2678016B1
(en)
|
2011-02-23 |
2016-08-10 |
Intellikine, LLC |
Heterocyclic compounds and uses thereof
|
PE20140378A1
(es)
|
2011-02-25 |
2014-03-28 |
Irm Llc |
Compuestos y composiciones como inhibidores de la trk
|
EP3366698A1
(en)
|
2011-03-01 |
2018-08-29 |
Synergy Pharmaceuticals Inc. |
Guanylate cyclase c agonists
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
EP2755976B1
(en)
|
2011-09-15 |
2018-07-18 |
Novartis AG |
6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
|
JP6165733B2
(ja)
|
2011-09-16 |
2017-07-19 |
ノバルティス アーゲー |
N−置換ヘテロシクリルカルボキサミド類
|
WO2013038386A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Heterocyclic compounds for the treatment of cystic fibrosis
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
EP2793893A4
(en)
|
2011-11-23 |
2015-07-08 |
Intellikine Llc |
IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
WO2013149581A1
(en)
|
2012-04-03 |
2013-10-10 |
Novartis Ag |
Combination products with tyrosine kinase inhibitors and their use
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
CA2902348C
(en)
|
2013-02-25 |
2021-11-30 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
CA2905010A1
(en)
|
2013-03-12 |
2014-09-18 |
Abbvie Inc. |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
JP2016514671A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼのアゴニストおよびその使用
|
EP2968439A2
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
JP2016512835A
(ja)
|
2013-03-15 |
2016-05-09 |
インテリカイン, エルエルシー |
キナーゼ阻害剤の組み合わせ及びそれらの使用
|
CA2913737A1
(en)
|
2013-06-05 |
2014-12-11 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
CN105979959B
(zh)
|
2013-08-09 |
2021-11-30 |
阿德利克斯公司 |
用于抑制磷酸盐转运的化合物和方法
|
WO2015051293A2
(en)
|
2013-10-04 |
2015-04-09 |
Abbvie, Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
CN106458966B
(zh)
|
2014-04-24 |
2019-05-07 |
诺华股份有限公司 |
作为磷脂酰肌醇3-激酶抑制剂的吡嗪衍生物
|
MX2016013812A
(es)
|
2014-04-24 |
2017-03-09 |
Novartis Ag |
Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa.
|
CN106458980A
(zh)
|
2014-04-24 |
2017-02-22 |
诺华股份有限公司 |
作为磷脂酰肌醇3‑激酶抑制剂的氨基吡啶衍生物
|
WO2015198320A1
(en)
|
2014-06-24 |
2015-12-30 |
Insight Biopharmaceuticals Ltd. |
Methods of purifying antibodies
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
MX2017001461A
(es)
|
2014-07-31 |
2017-05-11 |
Novartis Ag |
Terapia de combinacion.
|
WO2016160976A2
(en)
|
2015-03-30 |
2016-10-06 |
Abbvie Inc. |
Monovalent tnf binding proteins
|
EP3078675A1
(en)
|
2015-04-10 |
2016-10-12 |
Ares Trading S.A. |
Induction dosing regimen for the treatment of tnf alpha mediated disorders
|
EP3257866A1
(en)
|
2016-06-17 |
2017-12-20 |
Academisch Medisch Centrum |
Modified anti-tnf antibody and use thereof in the treatment of ibd
|
JOP20190162A1
(ar)
|
2016-12-30 |
2019-06-27 |
Biocad Joint Stock Co |
تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
|
WO2020048827A1
(en)
|
2018-09-03 |
2020-03-12 |
Bayer Aktiengesellschaft |
1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
|
WO2020048828A1
(en)
|
2018-09-03 |
2020-03-12 |
Bayer Pharma Aktiengesellschaft |
5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
|
WO2020237096A1
(en)
|
2019-05-21 |
2020-11-26 |
Ardelyx, Inc. |
Combination for lowering serum phosphate in a patient
|
CA3139634A1
(en)
|
2019-06-10 |
2020-12-17 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
|
CN114341132A
(zh)
|
2019-08-28 |
2022-04-12 |
诺华股份有限公司 |
经取代的1,3-苯基杂芳基衍生物及其在治疗疾病中的用途
|
WO2023208941A1
(en)
|
2022-04-26 |
2023-11-02 |
Essilor International |
Photochromic optical article having a mirror coating
|